Concerns about test price gouging may lead to greater scrutiny of costs
COVID-19 Test Pricing: Know the Facts, Protect Your Lab’s Reputation
Category: Quadax Blog
Women Among the Hardest Hit Financially by COVID-19 Pandemic
Hospitals, Health Systems and Labs can tailor billing to help ease healthcare burden
UHC Deadline for Lab Test Registry Delayed Indefinitely
College of American Pathologists Presses UHC to Extend Delay
Four Challenges Facing Healthcare Providers in the COVID-19 Pandemic
There has arguably never been a time like this before in healthcare—when receiving maximum reimbursement for every patient is critical.
CMS Price Transparency Rule – What You Need to Know
Price transparency has always been a persistent issue in healthcare. When patients don’t understand what they are being charged and what they will owe it leads to financial stress on the patient and the possibility of not being able to pay their medical bills.
RCM Automation: Where to Focus or Further Refine
COVID-19 continues to disrupt healthcare delivery, which will pose financial challenges to both large and small organizations. Now is the right time to investigate automation to keep revenue flowing and optimize reimbursements.
Mitigating the Financial Consequences of COVID-19
Is it time to automate your RCM? Learn more about the advantages and how to evaluate if it would benefit your organization.
Navigating Reimbursement for Liquid Biopsy Cancer Testing
Thirty-eight percent of private payers now cover some type of ctDNA-based panel testing. Is your lab aware of evolving payment policies?
The Right Automation is More Important Than Ever
There are more technology-driven opportunities to ‘fix’ your RCM than ever before. With all the solutions out there, why aren’t healthcare organizations getting better results?
COVID-19: Insurers Exempt from Covering Workplace Testing
Must Cover “Medically Appropriate” Tests Only
The rapid rollout in March of the federal FFCRA (Families First Coronavirus Response Act) and CARES (Coronavirus Aid, Relief and Economic Security Act) Acts – and specifically section 6001 of the FFCRA, which defines requirements for insurers – has left providers, labs and insurers uncertain, at times, of their respective responsibilities for COVID-19 testing.
